LigaChem Biosciences enters into
an antibody discovery agreement with Trican Biotechnology
Daejeon, South Korea and New Taipei City, Taiwan
September 10th, 2025
NEWS PROVIDED BY
-
Option and license research collaboration includes antibodies generated from Trican’s SERAbody platform against target of interest.
-
Agreement will enable LigaChemBio to design, develop, and expand its proprietary pipeline of Antibody-Drug Conjugates (ADCs) with improved efficacy, safety, and tolerability compared to existing marketed products.
-
Trican will receive progress-dependent milestone payments with royalties on net sales upon commercialization.
LigaChem Biosciences Inc. (141080KS, hereinafter “LigaChemBio”) and Trican Biotechnology (“Trican”) based in New Taipei City, Taiwan on September 10th,2025 jointly announced a research collaboration and exclusive option and license agreement to develop and commercialize a novel ADC therapeutic using antibodies engineered by Trican.
Under the terms of the agreement, LigaChemBio will advance the development and commercialization of ADC products using antibodies generated by Trican. Trican will receive an upfront payment and is eligible to receive progress-dependent regulatory, development, and commercial milestone payments with additional royalties on net product sales.
“We are pleased to enter into a partnership with LigaChemBio with its industry-leading proprietary ADC technology platform,” said Sharon Wang, GM of Trican. “This agreement marks the beginning of a partnership with LigaChemBio to combine the speed and quality from our antibody discovery with ConjuAll technology to create differentiated first and best-in class ADCs with wide therapeutic window to provide potential new treatment options for oncology.”
“We are pleased to enter this agreement with Trican as we continue to expand our toolbox to maximize the value of our ADC platform.
We look forward to evaluating and bringing innovative candidates into the clinic,” said Dr. Yong-Zu Kim, CEO of LigaChemBio.
About LigaChem Biosciences
LigaChem Biosciences (LCB, KOSDAQ:141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology and ADC platform technology ConjuAll™. Since its foundation in 2006, LCB has focused on the research and development of Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics and anti-fibrotic based on proprietary platform technologies.
About Trican Biotechnology.
Trican Biotechnology, founded in 2015, focuses on monoclonal and multispecific antibody design and discovery with ex vivo SERAbodies (Sequentially Enriched Recombinant Antibodies) engineering methodology from its proprietary fully-human DART (Directed Antibody Response against Tumors/lesions) library with deep somatically hypermutated affinity, diversity, specificity, and developability against targets of interest. Trican engineers further formats SERAbodies for internal development or external partnerships.